A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). In this study, sorafenib was added to daunorubicin...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Uy, Geoffrey L., Mandrekar, Sumithra J., Laumann, Kristina, Marcucci, Guido, Zhao, Weiqiang, Levis, Mark J., Klepin, Heidi D., Baer, Maria R., Powell, Bayard L., Westervelt, Peter, DeAngelo, Daniel J., Stock, Wendy, Sanford, Ben, Blum, William G., Bloomfield, Clara D., Stone, Richard M., Larson, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2017
Assuntos:
Myeloid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637402/
https://ncbi.nlm.nih.gov/pubmed/29034366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003053
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares